FDA DEVICE FACTS
cobas EGFR MUTATION TEST v2
Roche Molecular Systems, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The cobas® EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti-coagulated peripheral whole blood.
The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 below in accordance with the approved therapeutic product labeling:
Table 1. Drug FFPET Plasma TARCEVA® (erlotinib) Exon 19 deletions and L858R Exon 19 deletions and L858R TAGRISSO™ (osimertinib) T790M
Patients with positive cobas ® EGFR Mutation Test v2 test results using plasma specimens for the presence of EGFR exon 19 deletions or L858R mutations are eligible for treatment with TARCEVA ® (erlotinib). Patients who are negative for these mutations by this test should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.
Drug safety and efficacy have not been established for the following EGFR mutations listed in Table 2 below that are also detected by the cobas ® EGFR Mutation Test v2:
Table 2. Drug FFPET Plasma TARCEVA® (erlotinib) G719X, exon 20 insertions, T790M, S768I and L861Q G719X, exon 20 insertions, T790M, S768I and L861Q TAGRISSO™ (osimertinib) G719X, exon 19 deletions, L858R, exon 20 insertions, S768I, and L861Q G719X, exon 19 deletions, L858R, exon 20 insertions, T790M, S768I, and L861Q
For manual sample preparation, FFPET specimens are processed using the cobas ® DNA Sample Preparation Kit and plasma specimens are processed using the cobas® cfDNA Sample Preparation Kit. The cobas z 480 analyzer is used for automated amplification and detection.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。